Headache
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Headache is a highly competitive landscape with 176 programs across 48 companies. The most active players are COMPASS Pathways, Eli Lilly, Solvay Pharmaceuticals. 57 therapies are approved with 24 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Onabotulinumtoxina
Vitae Pharmaceuticals Inc., an Allergan affiliate
Lidocaine Hydrochloride
Citius Pharmaceuticals, Inc.
Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Dexmedetomidine
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Prednisolone
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Analysis
Modality Breakdown
96%
Small molecule
203 of 212 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 212 classified programs, each share of the total. Modality classified for 100% of 222 pipeline programs.
Analysis
Trial Status
264
clinical trials
Clinical Trials
Trial Activity
264 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)